Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008 by Tabriz University.
Recruitment status was  Active, not recruiting
Information provided by:
Tabriz University
ClinicalTrials.gov Identifier:
First received: April 18, 2007
Last updated: January 26, 2008
Last verified: January 2008
The purpose of this study is to determine whether Tamsolusin or Prazosin are effective in the treatment of female voiding dysfunction(BOO)

Condition Intervention Phase
Neurogenic Bladder
Drug: tamsolusin
Drug: prazosin
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction

Resource links provided by NLM:

Further study details as provided by Tabriz University:

Primary Outcome Measures:
  • patient symptoms improvement(Standard questionare) [ Time Frame: every month untile 3 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Urodynamics parameters improvement [ Time Frame: three months later ] [ Designated as safety issue: Yes ]

Enrollment: 80
Study Start Date: July 2005
Estimated Study Completion Date: March 2008
Estimated Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
taking Tamsulosin
Drug: tamsolusin
0.4 mg /day
Other Name: Flomax
Active Comparator: 2
taking prasosin
Drug: prazosin
1 mg/day

Detailed Description:
Voiding dysfunction is not uncommon in Tabriz.About 20% of patients in female urology clinic of Tabriz university of medical sciences sufered from some degrees of voiding dysfunction (due to bladder imparement or bladder outlet obstruction).There is limited information about medical treatment of those patients. On the other hand alpha adrenergic blockers are the first choice medication in BENIGN PROSTATIC HYPERPLASIA. There is some new facts about destribution of alpha adrenergic blockers in female pelvic floor.The purpose of this study is to comparision whether Tamsolusin 0.4/daily or Prazosin 1 mg/daily are effective in the treatment of female voiding dysfunction(BOO)

Ages Eligible for Study:   20 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy females with voiding difficulty with MFR<12 and post void residual urine>50cc

Exclusion Criteria:

  • History of pelvic floor surgury during last 3 month
  • Any contraindication for Tamsolusin or prazosin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00602186

Sponsors and Collaborators
Tabriz University
Study Director: SAKINEH hajebrahimi, MD Urology department ofTabriz University of Medical Sciences
  More Information

Responsible Party: Lily Nosraty, Tabriz University
ClinicalTrials.gov Identifier: NCT00602186     History of Changes
Other Study ID Numbers: 85-1 
Study First Received: April 18, 2007
Last Updated: January 26, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Tabriz University:
female voiding dysfunction

Additional relevant MeSH terms:
Urinary Bladder, Neurogenic
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Adrenergic Agents
Adrenergic Antagonists
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Urological Agents

ClinicalTrials.gov processed this record on May 02, 2016